/EMMAC acquires 100% of Terra Verde

EMMAC acquires 100% of Terra Verde

16 July 2019, London. EMMAC Life Sciences Ltd, the leading European independent medical cannabis and wellness company, is pleased to announce that it has acquired 100% of Terra Verde, LDA (“Terra Verde”), a Portuguese genetics and cultivation company. This acquisition establishes EMMAC as the largest vertically integrated cannabis company in Europe, with operations in eight territories and licensed distribution channels for medical cannabis in Europe’s largest medical cannabis markets, namely Germany, Italy and the UK.

Terra Verde holds oldest cannabis cultivation licence in Portugal, establishes EMMAC as the largest vertically integrated medical cannabis and wellness company in Europe.

The acquisition of Terra Verde is EMMAC’s largest acquisition to date and completes the full integration of EMMAC’s supply chain, which to date comprises GACP cultivation, extraction and manufacturing in accordance with EU Good Manufacturing Practices (GMP), and licensed distribution channels for medical cannabis in the UK, Germany and Italy.

Terra Verde was founded by David Yarkoni, a world-renowned breeder and geneticist who has pioneered plant-based research and production for more than 30 years. In 2014, Terra Verde acquired Portugal’s first, and Europe’s second, active cultivation license. This license allows for eight hectares of greenhouse and outdoors cannabis cultivation. Its current crop of high-grade medical cannabis, which is grown in accordance with EU Good Agricultural and Collection Practices (GACP), is due for harvest in 30 days.

Following completion of the acquisition, EMMAC will begin to invest significantly in Terra Verde’s facilities, including the construction of a GMP-certified facility for storage, processing and manufacturing at the Portuguese site that will serve both the domestic and the international markets.

Antonio Costanzo, CEO of EMMAC, commented: “We are delighted to have acquired Terra Verde, a unique asset in the European medical cannabis space that was founded by one of the most well-regarded plant-based researchers. With the acquisition of Terra Verde, EMMAC is now the largest vertically integrated European cannabis company and a leader in the industry. We are delighted to welcome David and his team in Portugal to EMMAC.

“With this milestone firmly achieved, EMMAC’s focus now is to extend the pan-European reach of our medical and wellness portfolio. We will continue to partner with the best organisations and businesses in the sector and support cutting-edge scientific research to further develop the medical cannabis sector.”

David Yarkoni, Founder of Terra Verde, commented: “Speaking on behalf Terra Verde’s team and shareholders, I am delighted to partner with EMMAC to maximise Terra Verde’s potential to be the best cultivation facility in Europe. We had been approached by multiple organisations, however we decided to partner with EMMAC due to its distribution network, world-class team and scientific approach. EMMAC has built the perfect platform to become the European leader. We look forward to working together.” 

About EMMAC

EMMAC is the European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production.  With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.

Contact:

For scientific enquiries please contact [email protected]

For general enquiries please contact [email protected] or visit www.emmac.com

Media enquiries:

Buchanan
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000
[email protected] www.buchanan.uk.com

CAUTIONARY STATEMENT

All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Ltd.  There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements.  These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice.  EMMAC Life Sciences Ltd assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.